34 results
Thumbnail

D1.189 - Does Allergen Immunotherapy Add Clinically Meaningful Benefit in Paediatric Asthma and Allergic Rhinitis? A 36-Month Real-World Comparison

Thumbnail

D1.192 - Combined Polymerized Pollen and Animal Dander Immunotherapy Improves Rhinoconjunctivitis and Asthma in Polysensitized Patients: Real-World Evidence

Thumbnail

D1.194 - Real-World Effectiveness of Polymerized Dog Allergen Immunotherapy in Allergic Rhinoconjunctivitis and Asthma

Thumbnail

D1.195 - Fc-Engagers as a targeted approach for antigen-specific immune inhibition in HDM allergy

Thumbnail

D1.197 - Safety and efficacy of a modified one-day ultra-rush protocol for the induction of Hymenoptera venom immunotherapy in patients with anaphylaxis in Switzerland

Thumbnail

D1.186 - Three years treatment with HDM injection allergen immunotherapy, omalizumab, or combination therapy in allergic asthma

Thumbnail

D1.187 - A Novel Volume-Reduced Desensitization Protocol for Pembrolizumab Hypersensitivity in Advanced Lung Cancer

Thumbnail

D1.188 - Adverse Reactions During Honey Bee Venom Immunotherapy as an Indicator of Underlying Clonal Mast Cell Disease Independent of Baseline Serum Tryptase: A Case Report

Thumbnail

D1.191 - Respiratory bacterial lysate (OM-85)-loaded dissolving microneedle array patch modulates HDM-induced allergic airway inflammation and airway hyperresponsiveness in a murine asthma model

Thumbnail

D1.198 - Efficacy of Cat Allergen Immunotherapy: A Multicenter Prospective Study

Thumbnail

D1.199 - Severe vernal keratoconjunctivitis with allergic rhinitis treated with house dust mite (HDM) sublingual immunotherapy (SLIT)

Thumbnail

D3.440 - Long-Term Efficacy and Safety of Donidalorsen for Hereditary Angioedema Among Patients in Europe: A Regional Analysis of the OASISplus Study

Thumbnail

D3.441 - Switching to Donidalorsen for Hereditary Angioedema: 1-Year Results From the Phase 3 OASISplus Study

Thumbnail

D3.444 - Efficacy and Safety of Donidalorsen for Patients With Hereditary Angioedema in Europe Who Switched From Prior Long-Term Prophylaxis: Results From the OASISplus Study

Thumbnail

D3.445 - Validation of a Novel Serum-Based Indirect Basophil Activation Test (iBAT) to Evaluate Efficacy of a Pivotal Phase III PQ Grass Immunotherapy Trial

Thumbnail

D3.437 - Impact of benralizumab on fatigue and health-related quality of life in patients with hypereosinophilic syndrome: findings from the NATRON phase 3 trial

Thumbnail

D3.438 - Clinical outcomes with navenibart according to baseline attack rate, body mass index, and age: results of the ALPHA-STAR trial

Thumbnail

D3.439 - Donidalorsen For The Treatment Of Hereditary Angioedema: 1-Year Results From The OASISplus Open-Label Extension Cohort

Thumbnail

D3.442 - Patient-Reported Outcomes With Long-Term Donidalorsen Treatment Among Patients In Europe With Hereditary Angioedema: 1-Year Interim Results From The OASISplus Open-Label Extension Cohort

Thumbnail

D3.443 - Patient-Reported Outcomes With Long-Term Donidalorsen Treatment Among Patients In Europe With Hereditary Angioedema: 1-Year Interim Results From The OASISplus Switch Cohort